Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Huijie HuangCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2471-8351
Christina Huan ShiCenter for Data Sciences, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Wenqi YangCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0009-0002-1107-741X
Juan C Piña-CrespoCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2803-7377
Jay BhatnagarCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0009-0001-5803-6319
Julian CuratoloCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0009-0004-4894-2459
Rabi MuradBioinformatics Shared Resource, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0009-0004-5297-8307
Palak ShahCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Alex CamposProteomics Core Facility, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Alexandra HouserCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-5516-6225
Rebecca A PorrittNCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-0973-5092
Giau Van VoCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-9937-7865
Qiang XiaoDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Tongmei ZhangCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Shengjie FengCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-2655-7726
Kevin Y YipCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-5516-9944
Timothy Y HuangCenter for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3504-9459
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Novel roles for the Alzheimer's Disease (AD) risk gene, SORLA in neuroprotection in ADR01AG061875 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HUANG, TIMOTHY YIKAI · 2018 to 2022
$3.4M
Elucidating a microgliaassociated role for SORLA in modulating AD pathogenesisRF1AG070391 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HUANG, TIMOTHY YIKAI · 2022 to 2022
$2.8M
Novel Neuroprotective Roles for the Alzheimer's Disease Risk Gene SORLA in Tau Pathology and PathogenesisR01AG085498 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Timothy Yikai Huang · 2024 to 2026
$2.6M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
Digital Spatial Profiler Analysis InstrumentS10OD030285 · OD · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ADAMS, PETER D. · 2021 to 2021
A role for the trafficking receptor SORLA (Sortilin-related receptor containing LDLR class A repeats) in reducing Aβ levels has been well established; however, relatively little is known with respect to whether and how SORLA can potentially affect tau pathology in vivo. Here, we show that transgenic SORLA up-regulation (SORLA TG) can attenuate pathological effects in aged PS19 (P301S tau) mouse brain, including tau phosphorylation and seeding, ventricle dilation, synapse loss, long-term potentiation (LTP) impairment, and glial hyperactivation. Proteomic analysis indicates attenuation of PS19 profiles in PS19/SORLA TG hippocampus, including pathological changes in synapse-related proteins and key drivers of synaptic dysfunction such as ApoE and C1q. Single-nucleus RNA sequencing analysis reveals suppression of PS19 signatures with SORLA up-regulation and identifies a previously unrecognized involvement of Sema4D-PlexinB1/B2 signaling in glial pathology. In contrast, SORLA deletion exacerbates tau seeding and aggregation, glial hyperactivation, and PlxnB1/B2 induction in PS19 hippocampus. These results indicate that SORLA confers neuroprotection against tau toxicity in the PS19 mouse brain.
Indexed as
AgingBrainLDL-Receptor Related ProteinsMembrane Transport ProteinsTauopathiesUp-RegulationAnimalsDisease Models, AnimalHippocampusHumansLong-Term PotentiationMiceMice, TransgenicNeurogliaReceptors, LDLSynapsesLDL-Receptor Related ProteinsMembrane Transport ProteinsReceptors, LDLSorl1 protein, mousetau Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain. · full record | OpenQuestion